News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
239,872 Results
Type
Article (6147)
Company Profile (26)
Press Release (233699)
Multimedia
Podcasts (3)
Webinars (4)
Section
Business (83743)
Career Advice (477)
Deals (15244)
Drug Delivery (12)
Drug Development (20618)
Employer Resources (30)
FDA (3866)
Job Trends (4003)
News (123465)
Policy (7800)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (384)
Accelerated approval (7)
Adcomms (4)
Allergies (18)
Alliances (15336)
ALS (41)
Alzheimer's disease (313)
Antibody-drug conjugate (ADC) (45)
Approvals (3964)
Artificial intelligence (89)
Autoimmune disease (28)
Automation (6)
Bankruptcy (99)
Best Places to Work (2948)
BIOSECURE Act (1)
Biosimilars (34)
Biotechnology (25)
Bladder cancer (50)
Brain cancer (7)
Breast cancer (103)
Cancer (966)
Cardiovascular disease (73)
Career advice (406)
Career pathing (3)
CAR-T (68)
CDC (2)
Cell therapy (182)
Cervical cancer (5)
Clinical research (17836)
Collaboration (384)
Compensation (372)
Complete response letters (9)
COVID-19 (384)
CRISPR (15)
C-suite (343)
Cystic fibrosis (30)
Data (1453)
Denatured (1)
Depression (22)
Diabetes (105)
Diagnostics (2141)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (38)
Drug pricing (15)
Drug shortages (3)
Duchenne muscular dystrophy (36)
Earnings (43192)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (40197)
Executive appointments (434)
FDA (4659)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (358)
Gene editing (29)
Generative AI (7)
Gene therapy (110)
GLP-1 (225)
Government (465)
Guidances (200)
Healthcare (5187)
HIV (11)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (41)
Immuno-oncology (7)
Indications (20)
Infectious disease (423)
Inflammatory bowel disease (46)
Inflation Reduction Act (3)
Influenza (12)
Intellectual property (37)
Interviews (58)
IPO (7957)
IRA (3)
Job creations (1134)
Job search strategy (370)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (110)
Leadership (5)
Legal (2397)
Liver cancer (22)
Longevity (2)
Lung cancer (100)
Lymphoma (79)
Machine learning (3)
Management (10)
Manufacturing (151)
MASH (67)
Medical device (4086)
Medtech (4096)
Mergers & acquisitions (7703)
Metabolic disorders (295)
Multiple sclerosis (18)
NASH (7)
Neurodegenerative disease (60)
Neuropsychiatric disorders (14)
Neuroscience (580)
NextGen: Class of 2026 (1828)
Non-profit (765)
Now hiring (5)
Obesity (127)
Opinion (37)
Ovarian cancer (27)
Pain (29)
Pancreatic cancer (43)
Parkinson's disease (61)
Partnered (7)
Patents (58)
Patient recruitment (106)
Peanut (10)
People (25581)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5404)
Phase 2 (7830)
Phase 3 (6067)
Pipeline (2050)
Policy (20)
Postmarket research (647)
Preclinical (2269)
Press Release (66)
Prostate cancer (58)
Psychedelics (4)
Radiopharmaceuticals (111)
Rare diseases (200)
Real estate (1912)
Recruiting (8)
Regulatory (5788)
Reports (18)
Research institute (383)
Resumes & cover letters (71)
Rett syndrome (19)
RNA editing (3)
RSV (7)
Schizophrenia (49)
Series A (56)
Series B (54)
Sickle cell disease (15)
Special edition (1)
Spinal muscular atrophy (34)
Sponsored (7)
Startups (1061)
Stomach cancer (1)
Supply chain (14)
Tariffs (7)
The Weekly (2)
Vaccines (92)
Venture capital (10)
Weight loss (65)
Women's health (7)
Date
Last 7 days (155)
Last 30 days (595)
Last 365 days (9327)
2026 (824)
2025 (9484)
2024 (11513)
2023 (13658)
2022 (19198)
2021 (20283)
2020 (18778)
2019 (13678)
2018 (10558)
2017 (10409)
2016 (9601)
2015 (12624)
2014 (9947)
2013 (7993)
2012 (8646)
2011 (9110)
2010 (8915)
Location
Africa (193)
Alabama (21)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (12168)
Australia (1801)
California (3709)
Canada (1168)
China (187)
Colorado (143)
Connecticut (197)
Delaware (72)
Europe (26710)
Florida (551)
Georgia (93)
Idaho (25)
Illinois (172)
India (15)
Indiana (111)
Iowa (9)
Japan (168)
Kansas (37)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (385)
Massachusetts (2880)
Michigan (104)
Minnesota (211)
Mississippi (1)
Missouri (32)
Montana (17)
Nebraska (12)
Nevada (47)
New Hampshire (19)
New Jersey (1029)
New Mexico (5)
New York (859)
North Carolina (487)
North Dakota (4)
Northern California (1946)
Ohio (120)
Oklahoma (5)
Oregon (6)
Pennsylvania (619)
Puerto Rico (2)
Rhode Island (19)
South America (288)
South Carolina (18)
Southern California (1351)
Tennessee (65)
Texas (499)
United States (12830)
Utah (115)
Virginia (86)
Washington D.C. (18)
Washington State (305)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
239,872 Results for "mim corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
September 30, 2025
·
7 min read
Press Releases
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
June 23, 2025
·
8 min read
Press Releases
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
June 23, 2025
·
9 min read
Deals
GE HealthCare announces agreement to acquire MIM Software
GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide.
January 8, 2024
·
8 min read
Press Releases
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
February 7, 2025
·
7 min read
Press Releases
Biomerics Launches its New Vertically Integrated Metal Injection Molding (MIM) Services
October 17, 2024
·
3 min read
BioMidwest
MIM Software Becomes Majority Vendor for RPT in Centers of Excellence
MIM Software Inc., a leading global provider of medical imaging software, is bringing its personalized dosimetry application to a growing majority of healthcare centers, providing clinicians and patients with advanced treatment insights.
March 29, 2023
·
2 min read
BioMidwest
MIM Software Celebrates MTIC’s First Total-Body PET/CT Scanner
MIM Software Inc. is proud to support the efforts of the Melbourne Theronastic Innovation Centre (MTIC) in Melbourne, Victoria as they launch the use of the Siemens Biograph Vision Quadra PET/CT, one of the few such “all-organ” scanners in the world.
April 12, 2023
·
3 min read
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Business
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.
August 22, 2022
·
6 min read
1 of 23,988
Next